BriLife

BriLife
Reuven Rivlin and the first person to receive the BriLife vaccine look at the viewer alongside two nurses. The flag of Israel sits in the background.
The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Other namesBrilife
Routes of
administration		Intramuscular
ATC code
  • None

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]

References

  1. 1 2 Karpiński, Tomasz M.; Ożarowski, Marcin; Seremak-Mrozikiewicz, Agnieszka; Wolski, Hubert; Wlodkowic, Donald (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. ISSN 1838-7640. PMC 7778607. PMID 33408775.
  2. ↑ Bezbaruah, Rajashri; Borah, Pobitra; Kakoti, Bibhuti Bhushan; Al-Shar’I, Nizar A.; Chandrasekaran, Balakumar; Jaradat, Da’san M. M.; Al-Zeer, Munir A.; Abu-Romman, Saeid (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 96. doi:10.3389/fmolb.2021.635337. ISSN 2296-889X. PMC 8082173. PMID 33937326.
  3. 1 2 Pushparajah, Deborah; Jimenez, Salma; Wong, Shirley; Alattas, Hibah; Nafissi, Nafiseh; Slavcev, Roderick A. (1 March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. ISSN 0169-409X. PMC 7789827. PMID 33422546.
  4. ↑ Venkadapathi, Jeyanthi; Govindarajan, Venkat Kumar; Sekaran, Saravanan; Venkatapathy, Santhi (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. ISSN 2296-889X. PMC 8219860. PMID 34179072.
  5. ↑ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
  6. ↑ Scarabel, Lucia; Guardascione, Michela; Dal Bo, Michele; Toffoli, Giuseppe (1 March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. ISSN 1201-9712. PMC 7816887. PMID 33476760.
  7. ↑ Rabinovitch, Ari; Williams, Dan (12 July 2021). Grebler, Dan (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
  8. ↑ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
  9. ↑ Yahalom-Ronen, Yfat; Tamir, Hadas; Melamed, Sharon; Politi, Boaz; Shifman, Ohad; Achdout, Hagit; Vitner, Einat B.; Israeli, Ofir; Milrot, Elad; Stein, Dana; Cohen-Gihon, Inbar (16 December 2020). Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy Avraham, Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran & Tomer Israely. "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. ISSN 2041-1723. PMC 7745033. PMID 33328475.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.